Home > Insider Trading > Filing (0000899243-17-008992)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1631574	Wave Life Sciences Ltd.	WVE	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1657769	Partnership Limited Investment Sousei Shinsangyo Kagoshima	1-3-34 Meizan-Cho, Kagoshima City Kagoshima M0 891-0122		No	No	Yes	No
1657771	Masaharu Tanaka	C/O Kagoshima Shinsangyo Sousei Invest. L.p., 1-3-34 Meizan-Cho, Kagoshima City Kagoshima M0 891-0122		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares	Disposition	2017-03-29	433,825	$24.91	2,794,865	No	4	S	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnote

Footnotes

The aggregate purchase price for the 433,825 Ordinary Shares was 1,199,998,712 Japanese yen. The purchase price per share in Column 4 of Table I was calculated based on the aggregate purchase price divided by the number of Ordinary Shares sold. The purchase price per share is shown in U.S. dollars and was converted based on the currency exchange rate as of the transaction date, March 29, 2017, rounded to the nearest whole cent.
Shares held by Kagoshima Shinsangyo Sousei Investment Limited Partnership ("KSS"). Masaharu Tanaka, a director of the Issuer, is the representative director of Kagoshima Development Co., Ltd., the general partner of KSS and may be deemed to beneficially own the reported securities. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Tanaka disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Tanaka is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities.